Skin, hair & tissue science
GHK-Cu
Cell/laboratory researchGHK-Cu combines the peptide glycine-histidine-lysine with copper. It has attracted interest in skin and extracellular-matrix research. Cosmetic observations do not establish benefits for other routes or whole-body use.
Source review: September 9, 2026. Scientific evidence and trial records change over time.
01 · What is it?
The identity comes first.
GHK-Cu combines the peptide glycine-histidine-lysine with copper. It has attracted interest in skin and extracellular-matrix research. Cosmetic observations do not establish benefits for other routes or whole-body use.
Scientific classification: Copper-binding tripeptide complex
For example. Think of a small copper-binding partner participating in a repair-workshop environment, rather than a master regeneration switch.
02 · How does it work?
The signal, explained.
It binds copper, and experiments examine how skin-related cells respond to that complex. Changes in scaffold-building and remodeling activity have been observed, without establishing one universal receptor.
The key research focus is Copper coordination and extracellular-matrix-associated pathways. A target describes where an interaction may occur; it does not by itself establish a benefit.
Learn the Science · mechanism
GHK binds copper ions. Cell studies report effects on fibroblast activity, matrix-related gene expression and remodeling enzymes, but there is no single established receptor accounting for all proposed actions.
03 · What happens after the signal?
Follow the downstream effects.
Changes in matrix production and remodeling could influence tissue organization in experimental systems. Increased collagen-related markers are not the same as a clinically visible or durable skin outcome.
To connect this mechanism to a real-world outcome, researchers need to establish exposure at the target, measure the response and test whether the change matters in a controlled human study.
04 · What is it commonly researched for?
The questions researchers are asking.
Researchers have investigated fibroblasts, collagen-related processes, wound models and cosmetic skin applications.
These are areas of investigation, not promises about a Maison product.
05 · Body systems involved
Where the biology connects.
- Skin
- Includes barrier tissue, fibroblasts and hair follicles where applicable; cell findings are not automatically clinical outcomes.
06 · Receptor / target profile
The molecular reference card.
- Primary receptor or target
- Copper coordination and extracellular-matrix-associated pathways
- Secondary interactions
- No additional primary target established for the research claim discussed.
- Where it is found
- Skin
- Activation, inhibition or interaction
- GHK binds copper ions. Cell studies report effects on fibroblast activity, matrix-related gene expression and remodeling enzymes, but there is no single established receptor accounting for all proposed actions.
- Important downstream pathways
- Changes in matrix production and remodeling could influence tissue organization in experimental systems. Increased collagen-related markers are not the same as a clinically visible or durable skin outcome.
07 · Evidence quality
What carries weight—and what does not.
STRONGER EVIDENCE
Convincing replicated human evidence for the broad wellness claims is not established.
EMERGING HUMAN EVIDENCE
Limited topical/cosmetic human evidence is formulation-specific; it cannot validate systemic use.
EARLY / PRECLINICAL EVIDENCE
Much mechanistic evidence comes from cultured cells and tissue models.
UNKNOWN OR NOT WELL ESTABLISHED
Long-term outcomes, comparative benefit, clinically meaningful effects and safety for broad wellness use are not well established.
A familiar mechanism, a patent, a testimonial or a trial registration alone cannot establish human efficacy or product quality.
08 · Who is studying it?
Follow the original research.
No current sponsor-led clinical development program was verified for this exact research identity. This does not prove that no study exists; consult current records and distinguish related molecules.
Regulatory context: No approved medical use for this research identity was established in the sources reviewed. This is not a determination of authorization in every country. The research material discussed here must not be assumed equivalent to a licensed medicine.
VIEW CURRENT CLINICAL TRIALSRegistry links may include related compounds or historical studies. Read the exact intervention, sponsor, phase and latest update date. Recruitment status is specific to each trial.
09 · Research terminology
A small glossary for this page.
Target
The molecule or biological structure a compound interacts with.
Pathway
A sequence of cellular events connecting a signal to a response.
Preclinical
Research outside human clinical trials, including cells and animals.
fibroblast
A cell that makes and remodels structural material around cells.
Biomarker
A measurable biological feature. A change in a marker does not always translate into a meaningful health outcome.
Target engagement
Evidence that a compound actually reaches and interacts with the intended biological target.
Randomized controlled trial
A study that assigns participants by chance to comparison groups, helping separate an intervention’s effects from other influences.
10 · Research status & limitations
Keep the boundaries visible.
No approved medical use for this research identity was established in the sources reviewed. This is not a determination of authorization in every country. The research material discussed here must not be assumed equivalent to a licensed medicine.
Long-term outcomes, comparative benefit, clinically meaningful effects and safety for broad wellness use are not well established.
The main evidence category here is cell/laboratory research. The exact molecule, formulation, study population and endpoint matter. Scientific evidence changes; this page is a dated educational summary, not continuous trial monitoring.
11 · References / continue reading
Go to the source.
Individual study links support the associated research discussion. Literature-search links are clearly labelled and help you explore further; they are not themselves proof of a claim. Sponsor announcements should be read alongside published papers and current regulatory records.